Advertisement
Advertisement
CTOR
Citius Oncology, Inc. Common Stock
0.75
USDSponsored
-0.01
-0.92%
Aug 07, 15:57 UTC -4
Closed
Pre-Market
0.78
+0.02
+2.92%
CTOR Earnings Reports
Positive Surprise Ratio
CTOR beat 2 of 6 last estimates.
33%
Next Report
Today
Date of Next Report
Aug 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.55M
/-$0.05
Implied change from Q2 26 (Revenue/ EPS)
+52.97%
/-81.48%
Implied change from Q3 25 (Revenue/ EPS)
--
/-37.50%
Citius Oncology, Inc. Common Stock earnings per share and revenue
On May 15, 2026, CTOR reported earnings of -0.27 USD per share (EPS) for Q2 26, missing the estimate of -0.01 USD, resulting in a -2547.06% surprise. Revenue reached 1.67 million, compared to an expected 7.14 million, with a -76.64% difference. The market reacted with a -13.95% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.05 USD, with revenue projected to reach 2.55 million USD, implying an decrease of -81.48% EPS, and increase of 52.97% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Edgewise Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.53
Surprise
-10.55%
Denali Therapeutics Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.66
Actual
-$0.68
Surprise
-1.51%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
FAQ
What were Citius Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Citius Oncology, Inc. Common Stock reported EPS of -$0.27, missing estimates by -2547.06%, and revenue of $1.67M, -76.64% below expectations.
How did the market react to Citius Oncology, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -13.95%, changed from $0.96 before the earnings release to $0.83 the day after.
When is Citius Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Citius Oncology, Inc. Common Stock's next earnings report?
Based on 3
analysts, Citius Oncology, Inc. Common Stock is expected to report EPS of -$0.05 and revenue of $2.55M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement